Evidence map›Paper›PMID 39567199›Full record

ArticleCancer reports (Hoboken, N.J.)2024

Outcomes of Cancer Patients Affected by COVID-19 in Different Settings: A Retrospective Study in Lebanon.

Ahmad El Mahmoud, Elie Jean Karam, Reine Abou Zeidane, Wafaa Khaled, Youssef Zougheib, Joe David Azzo, Hussein El Jebbawi, Ali Atoui, Razan Mohty, Tasnim Diab and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ahmad El MahmoudDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K Bassile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Elie Jean KaramFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Reine Abou ZeidaneDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K Bassile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Wafaa KhaledDepartment of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Youssef ZougheibFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Joe David AzzoFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Hussein El JebbawiFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Ali AtouiDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K Bassile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.ORCID 0000-0002-9667-3634
Razan MohtyDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K Bassile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Tasnim DiabDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K Bassile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Iman Abou DalleDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K Bassile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.ORCID 0000-0002-6520-9134
Maya CharafeddineDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K Bassile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Hazem I AssiDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K Bassile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.ORCID 0000-0002-8483-0938

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe diverse presentation of COVID-19 symptoms and outcomes has revealed a significant gap in understanding the specific risk factors and characteristics of the virus among immunocompromised cancer patients, particularly in the Middle East.

aimsWe our study aimed to address this gap by investigating the characteristics and outcomes of COVID-19 in cancer patients compared to non-cancer patients. METHODS AND

resultsWe carried out a retrospective analysis, collecting demographic, oncologic, and COVID-19-related data from electronic medical records of 248 patients admitted to our tertiary care center in Lebanon. Statistical analysis was conducted using SPSS to identify patterns. Patients with solid tumors were 3.433 times more likely to die than those who were cancer-free (p = 0.012). Moreover, patients with advancing disease were 2.805 times more likely to be admitted to the ICU (p = 0.03) and 14.7 times more likely to die (p < 0.001) compared with those in remission.

conclusionOur findings emphasize the critical need for tailored preventive measures and specialized care for immunocompromised cancer patients, given their heightened vulnerability to severe COVID-19 outcomes. These insights contribute to the development of specific strategies aimed at enhancing the protection and clinical management of this high-risk group.

Indexed as

COVID-19NeoplasmsSARS-CoV-2AdultAgedAged, 80 and overFemaleHospitalizationHumansImmunocompromised HostIntensive Care UnitsLebanonMaleMiddle AgedRetrospective StudiesRisk FactorscancercomorbiditiesCOVID‐19disease severityintensive care unitintubationrisk factors

Identifiers

PMID39567199
PMCPMC11578677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.